As a long-time leader in neuroscience, Jazz has held a longstanding commitment to provide therapies and support for patients living with serious, debilitating neurologic disorders, to help them reclaim their lives. Even though essential tremor (ET) is considered the most common movement disorder, affecting millions of people worldwide,1 there are limited treatment options for patients.
People living with ET experience an abnormal and involuntary rhythmic shaking (tremor) that most commonly affects the hands and arms, but tremor can also occur in the head, voice, and lower limbs. As a result of this serious condition, people living with ET can struggle to perform daily activities (e.g., eating, dressing, and personal hygiene) and function socially.
The first and only approved FDA-approved medicine for the treatment of ET was approved over 50 years ago.2 It is estimated that up to half of patients do not respond to first-line therapy, and over 50% of patients reportedly discontinue medication due to lack of efficacy and/or side effects.3,4 There is a clear and urgent need for new treatment options for patients with ET, and we believe developing medicines that can improve the day-to-day functioning of patients with ET aligns with our mission to provide life-changing medicines.
Jazz is currently investigating a potential new therapy, a highly selective modulator of T-type calcium channels, for the treatment of moderate to severe ET. Many neurologic disorders, including ET, are characterized by abnormal rhythms in certain regions of the brain mediated by T-type calcium channels, which are important for controlling movement.5,6 The mechanism through which our investigational therapy is thought to improve tremor in patients with ET is unique from all currently utilized medicines for patients with ET and may thus represent a meaningful advancement in the treatment of the condition.7
Our investigational treatment has already been evaluated in a Phase 2a randomized, placebo-controlled clinical study in adults with ET. Results of that study provided proof-of-concept data to support it as a promising candidate for ET and have recently been published in the peer-reviewed journal Movement Disorders.8
As a next step in development, Jazz has initiated a Phase 2b clinical study (the EveresT study) of a once-daily formulation of the potential new treatment in adult patients with moderate to severe ET. The study is being conducted by doctors in the U.S., Germany, Poland, and Spain. The outcome measures used are focused on assessing changes in day-to-day functioning due to tremor. If you would like to learn more information about the trial, including whether you are eligible, please visit www.EveresTstudy.com.
Thank you! We'll get back to you shortly.
Please select and enter the required fields on the form below. We need this information to process your request and to take necessary steps to verify your identity.
We will contact you if we need any additional information
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.